Epicyn regulatory update

Oculus said Mexico approved Epicyn to manage hypertrophic and keloid scarring. A launch of the product is slated for summer. Oculus said it will conduct an additional clinical trial next half with partner More Pharma Corp. (Mexico City, Mexico) to evaluate Epicyn vs. current standard of care in Mexico. More Pharma has rights to Oculus' Microcyn-based products in Mexico, South and Central America, and the Caribbean (see BioCentury, Aug. 20, 2012). ...